环氧化酶-2在肝细胞癌中的表达及临床意义

目的 观察环氧化酶-2(COX-2)在肝细胞癌(HCC,简称肝癌)中的表达特征.方法 应用免疫组织化学S-P法、逆转录聚合酶链反应检测重庆医科大学附属第二医院2005年10月至2007年6月手术切除并经病理切片证实的52例HCC标本、52例癌旁组织及10例正常肝组织中COX-2及其基因的表达情况.结果 COX-2/COX-2 mRNA在肝癌组织中的表达明显上调,与其在正常肝组织、癌旁组织中的表达相比差异有统计学意义(P<0.01).结论 (1)COX-2高表达参与了肝癌的发生和发展,其表达水平与肝癌的分化程度及是否合并乙型肝炎及肝硬化有关,与HCC组织的国际癌症病期分期、肿瘤大小、甲胎蛋白水平、大体类型及是否转移等无明显关系.(2)COX-2抑制剂有望为预防HCC的发生和发展提供一条新的途径.     

肝细胞癌组织和血清中肝细胞生长因子的临床意义

目的 探讨肝细胞生长因子(HGF)在慢性肝炎、肝硬化、肝细胞癌(HCC)患者肝组织和血清中的表达水平及其临床意义.方法 收集2003年12月至2008年8月期间天津市第三中心医院11份正常、6份肝炎、20份肝硬化、60份HCC组织(高分化21份、中分化23份、低分化16份),及其癌旁0、1、2、3 cm组织(N0、N1、N2、N3)各24、21、54和43份.用实时荧光定量逆转录(RT)-PCR分析不同肝组织HGF mRNA表达;同时,用ELISA测定健康体检者、肝炎、肝硬化患者血清标本各20份及HCC患者57份术前1d、术后1周内血清标本的HGF浓度.多组间组织HGF mRNA水平比较用Kruskal-Wallis检验,两组间组织HGF mRNA水平比较用Mann-Whitney U检验.多组间血清HGF浓度比较用单因素方差分析,两组间血清HGF浓度比较用LSD-t检验.性别、年龄、肿瘤类型、肿瘤直径等临床因素对HCC患者组织、血清HGF水平的影响及其与患者预后的相关分析分别用Logistic回归分析及Cox比例风险模型.筛选出影响患者术后生存的独立预后指标,以中位数水平分层,由Kaplan-Meier生存曲线计算不同分层水平的死亡终点事件发生风险,并用Log-rank检验评价分层间死亡终点事件发生率.结果 实时荧光定量RT-PCR检测健康对照组、肝炎、肝硬化、N3、N2、N1、N0、HCC组HGF mRNA表达分别为0.99(0.78～1.66)、2.15 (1.06～3.40)、1.78(1.18～2.73)、4.59(2.67 ～8.63)、3.86(2.25 ～6.45)、3.12(1.59 ～5.74)、2.92(0.88 ～5.99)、0.48(0.19～1.06);ELISA检测血清HGF在健康体检者、肝炎、肝硬化及HCC患者术前1d、术后1周的浓度分别为(0.31±0.05)、(0.65±0.07)、(1.27 ±0.30)、(2.06±0.66)及(2.14±0.52)μg/L.不同肝组织相比,HGF mRNA在N3组织中表达最高,而在HCC组织中的表达不仅低于以上各良性肝病组织,而且低于正常肝组织(U=196.50,P=0.03);不同血清HGF浓度相比,HGF在肝炎、肝硬化、HCC患者血清中的浓度均明显高于健康对照组,且HCC患者术后1周的血清HGF浓度高于其术前血清HGF浓度(t=2.70,P＜0.01);Logistic回归分析显示,HCC患者癌组织及血清HGF水平分别受肿瘤数目及Child-pugh肝功能分级影响,OR分别为0.15(95％ CI:0.03 ～0.72,P＜0.05)和0.13(95％口:0.27 ～0.89,P＜0.05).Cox比例风险模型分析显示,肿瘤组织HGF mRNA水平、血清HGF浓度是影响HCC患者术后生存的独立预后指标,OR分别为0.02(95％ CI:0.00 ～0.52,P＜0.05)和10.01(95％CI:1.16 ～86.23,P＜0.05).以肿瘤组织HGF mRNA 2-AACT中位数0.49对HCC患者进行分层分析显示,两组患者术后累计生存率差异无统计学意义(x2=0.13,P=0.72).以血清浓度中位数0.69 μg/L对HCC患者进行分层分析,HGF≥0.69 μg/L的HCC患者,其术后死亡的风险是HGF＜0.69 μg/L患者的2.84倍(95％ CI:1.03 ～7.92,P＜0.05).结论 HCC患者癌组织中HGF mRNA表达降低,但癌旁组织HGF mRNA表达和血清HGF浓度明显升高,且血清HGF浓度影响患者预后,检测血清HGF有望用于评估HCC患者预后.     

人锌指蛋白23在原发性肝细胞肝癌中的表达及临床意义

目的 分析hZNF23在人HCC组织及HepG2细胞系中的表达情况,以探讨其与HCC临床病理特征和细胞凋亡的关系.方法 采用实时荧光定量RT-PCR法检测37例HCC患者(按Edmondson分为两组,Ⅰ+Ⅱ级17例,Ⅲ+Ⅳ级20例;按临床分为3组,HCC合并肝硬化和HBV感染组31例,HCC合并肝硬化和HCC合并HRV感染组各3例)癌组织和其癌旁肝组织标本中hZNF23及内参GAPDH mRNA的表达水平,并分析其与HCC临床病理特征的关系;体外培养HepG2细胞后,分为4组(对照组、1.25、2.5和5 μg/ml顺铂组)或6组(对照组、1.25、2.5、5、10和20μg/ml顺铂组).采用四唑盐比色法(MTT)和流式细胞仪膜联蛋白V/碘化丙啶染色法检测与观察HepG2细胞的增殖及凋亡情况;实时荧光定量RT-PCR法检测HepG2细胞在不同浓度的顺铂诱导凋亡后,hZNF23及内参GAPDH mRNA的表达水平.结果 37例HCC患者癌组织及其癌旁组织标本中hZNF23相对表达量分别为8.84(3.59～15.05)和22.20(13.85～42.90),差异有统计学意义(U=259.5,P＜0.01).Edmondson Ⅰ+Ⅱ级HCC组织hZNF23 mRNA相对表达量为12.80(4.80～19.50),高于Ⅲ+Ⅳ级的5.01(2.88～11.68),且差异有统计学意义(U=99.00,P＜0.05);合并肝硬化组为9.92(3.80～15.25),未合并肝硬化组为3.21(2.78～3.60)、合并HBV感染组为9.09(3.72～15.25),无HBV感染组为2.48(1.79～12.10),合并肝硬化组与未合并肝硬化组、合并HBV感染组与未合并HBV感染组比较,其hZNF23 mRNA表达量差异均无统计学意义(U值分别为16.00和24.00,P均＞0.05).顺铂作用于HepG2细胞24 h后,用MTT检测,顺铂明显抑制HepG2细胞增殖;膜联蛋白V/碘化丙啶染色法检测细胞凋亡率依次为(0.9±0.2)%、(4.2±0.3)%、(9.8±4.3)%、(23.0±6.0)%,顺铂显著诱导HepG2细胞凋亡,且呈剂量依赖性(F=27.890,P＜0.01).实时荧光定量RT-PCR法检测1.25、2.5、5μg顺铂诱导的HepGR细胞组hZNF23 mRNA相对表达量依次为(10.39±3.08)×10-5、(24.10±2.09)×10-5、(6.90±2.24)×10-4,均显著高于对照组[(9.48±1.80)×10-5,F=6.027,P＜0.01].结论 HCC组织中hZNF23相对表达水平与Edmondson分级密切关联;顺铂对HepG2细胞的凋亡作用可能与hZNF23上调有关.

Abstract：

Objective To detect the expression level of human zinc finger 23 (ZNF23) in hepatocellular carcinoma tissue samples and HepG2 cell lines and investigate the relationship between hZNF23 expression and clinicopathological characteristics of HCC and cell apoptosis. Methods The expression levels of hZNF23 and GAPDH mRNA in 37 cases of HCC were measured by real-time RT-PCR. The association between the expression of hZNF23 and the clinicopathological characteristics of HCC was analyzed. Cultured HepG2 cells were divided into 4 groups ( control group, 1.25 μg/ml , 2.5 μg/ml and 5 μg/ml cisplatin)or 6 groups( control group, 1.25 μg/ml, 2.5 μg/ml, 5 μg/ml, 10 μg/ml and 20 μg/ml cisplatin). MTT method was employed to evaluate cell proliferation. Annexin V-FITC assay was used to assess percentage of apoptotic HepG2 cells. The expression levels of hZNF23 and GAPDH mRNA of HepG2 cells after apoptosis induced by cisplatin with a series of concentrations were measured by real-time RT-PCR.Results The median ( quartile1, quartile 3) expression levels of hZNF23 mRNA in 37 HCC tissue samples and adjacent tissue samples were 8.84 (3.59-15.05), 22.20 ( 13.85-42.90 ), respectively. There was significant difference ( U = 259.5, P ＜ 0.01 ). The median ( quartile1, quartile 3 ) expression levels of hZNF23 mRNA in cancer tissue samples with Edmondson stage Ⅰ + Ⅱ [12.80(4.80-19.50)] was much higher than those in stage Ⅲ + Ⅳ [5.01 ( 2.88-11.68 ), U = 99.00, P ＜ 0.05] The median ( quartile1,quartile 3 ) expression levels of hZNF23 mRNA in patients with and without hepatic cirrhosis were 9.92(3.80-15.25) , 3.21 (2.78-3.60), respectively. The median ( quartile1, quartile 3 ) expression levels of hZNF23 mRNA in HBV infection and non-infection patients was 9.09(3.72-15.25 ), 2.48 (1.79-12.10),respectively. There was no significant difference between groups with and without hepatic cirrhosis and between HBV infection and non-infection groups( U = 16. 00 and 24.00, P ＞0.05 ). MTT assay indicated that cisplatin significantly inhibited HepG2 cells proliferation in a dose-dependent manner. Annexin V-FITC/PI assay showed that HepG2 cells apoptosis rates were (0.9 ± 0.2 ) %, ( 4. 2 ± 0.3 ) %, ( 9.8 ± 4. 3 ) %,(23.0 ± 6.0)%, respectively. Cisplatin significantly induced HepG2 cells apoptosis in a dose-dependent manner( F = 27.89, P ＜ 0.01 ). The expression levels of hZNF23 mRNA in cisplatin groups [( 10.39 ±3.08) × 10-5, (24.10 ± 2.09) × 10-5, (6.90 ± 2.24) × 10-4] were significantly lower than that of the controlgroup[(94.80±1.80) ×10-5, F=6.027, P＜0.01]. Conclusions The expression level hZNF23 mRNA is related to Edmondson stage of HCC. The apoptosis effect of cisplatin on HepG2 cells may be associated with the upregulation of hZNF23.     

人锌指蛋白23在原发性肝细胞肝癌中的表达及临床意义

Objective To detect the expression level of human zinc finger 23 (ZNF23) in hepatocellular carcinoma tissue samples and HepG2 cell lines and investigate the relationship between hZNF23 expression and clinicopathological characteristics of HCC and cell apoptosis. Methods The expression levels of hZNF23 and GAPDH mRNA in 37 cases of HCC were measured by real-time RT-PCR. The association between the expression of hZNF23 and the clinicopathological characteristics of HCC was analyzed. Cultured HepG2 cells were divided into 4 groups ( control group, 1.25 μg/ml , 2.5 μg/ml and 5 μg/ml cisplatin)or 6 groups( control group, 1.25 μg/ml, 2.5 μg/ml, 5 μg/ml, 10 μg/ml and 20 μg/ml cisplatin). MTT method was employed to evaluate cell proliferation. Annexin V-FITC assay was used to assess percentage of apoptotic HepG2 cells. The expression levels of hZNF23 and GAPDH mRNA of HepG2 cells after apoptosis induced by cisplatin with a series of concentrations were measured by real-time RT-PCR.Results The median ( quartile1, quartile 3) expression levels of hZNF23 mRNA in 37 HCC tissue samples and adjacent tissue samples were 8.84 (3.59-15.05), 22.20 ( 13.85-42.90 ), respectively. There was significant difference ( U = 259.5, P ＜ 0.01 ). The median ( quartile1, quartile 3 ) expression levels of hZNF23 mRNA in cancer tissue samples with Edmondson stage Ⅰ + Ⅱ [12.80(4.80-19.50)] was much higher than those in stage Ⅲ + Ⅳ [5.01 ( 2.88-11.68 ), U = 99.00, P ＜ 0.05] The median ( quartile1,quartile 3 ) expression levels of hZNF23 mRNA in patients with and without hepatic cirrhosis were 9.92(3.80-15.25) , 3.21 (2.78-3.60), respectively. The median ( quartile1, quartile 3 ) expression levels of hZNF23 mRNA in HBV infection and non-infection patients was 9.09(3.72-15.25 ), 2.48 (1.79-12.10),respectively. There was no significant difference between groups with and without hepatic cirrhosis and between HBV infection and non-infection groups( U = 16. 00 and 24.00, P ＞0.05 ). MTT assay indicated that cisplatin significantly inhibited HepG2 cells proliferation in a dose-dependent manner. Annexin V-FITC/PI assay showed that HepG2 cells apoptosis rates were (0.9 ± 0.2 ) %, ( 4. 2 ± 0.3 ) %, ( 9.8 ± 4. 3 ) %,(23.0 ± 6.0)%, respectively. Cisplatin significantly induced HepG2 cells apoptosis in a dose-dependent manner( F = 27.89, P ＜ 0.01 ). The expression levels of hZNF23 mRNA in cisplatin groups [( 10.39 ±3.08) × 10-5, (24.10 ± 2.09) × 10-5, (6.90 ± 2.24) × 10-4] were significantly lower than that of the controlgroup[(94.80±1.80) ×10-5, F=6.027, P＜0.01]. Conclusions The expression level hZNF23 mRNA is related to Edmondson stage of HCC. The apoptosis effect of cisplatin on HepG2 cells may be associated with the upregulation of hZNF23.     

人锌指蛋白23在原发性肝细胞肝癌中的表达及临床意义

Objective To detect the expression level of human zinc finger 23 (ZNF23) in hepatocellular carcinoma tissue samples and HepG2 cell lines and investigate the relationship between hZNF23 expression and clinicopathological characteristics of HCC and cell apoptosis. Methods The expression levels of hZNF23 and GAPDH mRNA in 37 cases of HCC were measured by real-time RT-PCR. The association between the expression of hZNF23 and the clinicopathological characteristics of HCC was analyzed. Cultured HepG2 cells were divided into 4 groups ( control group, 1.25 μg/ml , 2.5 μg/ml and 5 μg/ml cisplatin)or 6 groups( control group, 1.25 μg/ml, 2.5 μg/ml, 5 μg/ml, 10 μg/ml and 20 μg/ml cisplatin). MTT method was employed to evaluate cell proliferation. Annexin V-FITC assay was used to assess percentage of apoptotic HepG2 cells. The expression levels of hZNF23 and GAPDH mRNA of HepG2 cells after apoptosis induced by cisplatin with a series of concentrations were measured by real-time RT-PCR.Results The median ( quartile1, quartile 3) expression levels of hZNF23 mRNA in 37 HCC tissue samples and adjacent tissue samples were 8.84 (3.59-15.05), 22.20 ( 13.85-42.90 ), respectively. There was significant difference ( U = 259.5, P ＜ 0.01 ). The median ( quartile1, quartile 3 ) expression levels of hZNF23 mRNA in cancer tissue samples with Edmondson stage Ⅰ + Ⅱ [12.80(4.80-19.50)] was much higher than those in stage Ⅲ + Ⅳ [5.01 ( 2.88-11.68 ), U = 99.00, P ＜ 0.05] The median ( quartile1,quartile 3 ) expression levels of hZNF23 mRNA in patients with and without hepatic cirrhosis were 9.92(3.80-15.25) , 3.21 (2.78-3.60), respectively. The median ( quartile1, quartile 3 ) expression levels of hZNF23 mRNA in HBV infection and non-infection patients was 9.09(3.72-15.25 ), 2.48 (1.79-12.10),respectively. There was no significant difference between groups with and without hepatic cirrhosis and between HBV infection and non-infection groups( U = 16. 00 and 24.00, P ＞0.05 ). MTT assay indicated that cisplatin significantly inhibited HepG2 cells proliferation in a dose-dependent manner. Annexin V-FITC/PI assay showed that HepG2 cells apoptosis rates were (0.9 ± 0.2 ) %, ( 4. 2 ± 0.3 ) %, ( 9.8 ± 4. 3 ) %,(23.0 ± 6.0)%, respectively. Cisplatin significantly induced HepG2 cells apoptosis in a dose-dependent manner( F = 27.89, P ＜ 0.01 ). The expression levels of hZNF23 mRNA in cisplatin groups [( 10.39 ±3.08) × 10-5, (24.10 ± 2.09) × 10-5, (6.90 ± 2.24) × 10-4] were significantly lower than that of the controlgroup[(94.80±1.80) ×10-5, F=6.027, P＜0.01]. Conclusions The expression level hZNF23 mRNA is related to Edmondson stage of HCC. The apoptosis effect of cisplatin on HepG2 cells may be associated with the upregulation of hZNF23.     

HBsAg阳性甲胎蛋白mRNA在肝癌组织中临床意义

目的：探讨甲胎蛋白mRNA在HBsAg阳性肝癌组织中表达的临床意义。方法：用巢式逆转录聚合酶链反应检测38例HBsAg阳性肝细胞癌患者癌组织甲胎蛋白mRNA。结果：32例（84．2％）患者癌组织甲胎蛋白mRNA呈阳性表达，其外周血甲胎蛋白mRNA亦为阳性；而阴性表达的6例（15．8％）其外周血甲胎蛋白mRHA和血清甲胎蛋白亦为阴性。HBsAg阳性癌组织甲胎蛋白mRNA阳性率在合并肝硬化组为100％，合并血清甲胎蛋白〉25ug／L组为100％、无合并肝硬化组为57．1％，〈25ug／L组为57．1％，P〈0．05。相关分析显示外周血甲胎蛋白mRNA阳性率和血清甲胎蛋白水平均于癌组织甲胎蛋白mRNA阳性表达呈正相关。癌组织甲胎蛋白RNA阳性表达与合并肝硬化呈正相关，而与有无门静脉癌栓或肝外转移及癌灶大小无相关性。结论：大多数HBsAg阳性肝细胞癌的甲胎蛋白基因处于活化状态，其外周血甲胎蛋白mRNA阳性表达和血清甲胎蛋白水平均与癌组织甲胎蛋白mRNA阳性表达有关。     

鼻咽癌患者外周血中CK20 mRNA的表达及其临床意义

目的研究鼻咽癌(NPC)患者外周血中CK20mRNA表达并探讨其临床意义。方法采用巢式逆转录和多聚酶链反应方法,对NPC伴颈淋巴结转移组19例和NPC颈部淋巴结无转移组13例(共计32例)CK20mRNA表达进行检测。CT证实两组患者均无远处转移病灶。对照组1为8例非肿瘤患者外周血;阳性对照分别为B95-8细胞株和NPC组织。结果NPC伴颈淋巴结转移组CK20mRNA阳性表达率为21.1%(4/19),颈部淋巴结无转移组为7.7%(1/13),两组间阳性表达率比较差异无显著性意义(P>0.05)。CK20mRNA阳性表达与鼻咽癌国际抗癌联盟分期无关。对照组1均为阴性表达。结论NPC患者外周血中CK20mRNA的阳性表达作为NPC细胞血行播散的指标可能是有价值的,有助于评估NPC患者的预后。     

RPA1在肝癌组织中的表达及临床意义的研究

目的观察复制蛋白A1(RPA1)在肝细胞肝癌组织中的表达并探讨其临床意义。方法应用逆转录聚合酶链反应(RT-PCR)和蛋白质印迹法(Western blot)检测30例肝细胞肝癌组织及癌旁组织中RPA1 mRNA及蛋白的半定量表达水平,结合临床病理资料,统计分析肝细胞肝癌患者中RPA1表达的临床意义。结果 RPA1 mRNA在肝细胞肝癌组织的表达高于癌旁组织(0.635±0.228 vs.0.448±0.186,P0.05)。RPA1蛋白在肝细胞肝癌组织的表达高于癌旁组织(0.876±0.205 vs 0.727±0.153,P0.05)。在肝细胞肝癌组织中,RPA1 mRNA的表达在临床分期Ⅰ+Ⅱ组低于Ⅲ+Ⅳ组,组间差异有统计学意义(0.471±0.190 vs.0.744±0.184,P0.05)。在肝细胞肝癌组织中,RPA1蛋白的表达在临床分期为Ⅰ+Ⅱ组低于Ⅲ+Ⅳ组,组间差异有统计学意义(0.742±0.155 vs.0.965±0.188,P0.05)。在肝细胞肝癌组织中,RPA1 mRNA和蛋白的表达水平在患者不同年龄、性别、肝癌组织分级、是否有乙肝表面抗原、淋巴转移、门脉癌栓等临床病理特征中差异无统计学意义(P0.05)。结论 RPA1在肝细胞肝癌组织中表达上调,其表达上调可能促进肝癌的发生和发展。     

实时定量逆转录PCR检测慢性淋巴细胞白血病中脂蛋白酯酶mRNA的表达及临床意义

目的 研究慢性淋巴细胞白血病(CLL)患者脂蛋白酯酶(LPL)表达情况,探讨LPL在CLL预后中的意义.方法 采用基于Taqman探针技术的实时定量逆转录PCR(qRT-PCR)方法检测62例CLL患者及10名健康对照者外周血标本中LPL的表达水平.对LPL表达水平与免疫球蛋白重链可变区(IgVH)基因突变、ZAP-70蛋白和CD38表达等预后因素进行相关性分析.采用ROC曲线确定LPL表达的最佳分界值,计算其对IgVH突变情况的阳性及阴性预测值.结果 qRT-PCR标准曲线的R2均≥0.990,敏感度可以检测到102拷贝/μg RNA,批内差及批间差变异系数(CV)均小于5%.62例CLL患者LPL表达水平中位数为0.006 0(0～0.737 0).在10名健康对照者中LPL均不表达或低表达,LPL中位表达水平为0(0～0.000 4).在经CD19磁珠分选后的3份CLL患者标本中,LPL相对表达量分别为0.036 0、0.075 0和0.197 0,与分选前表达水平(分别为0.024 0、0.074 0和0.225 0)相似.LPL表达水平与IgVH基因突变情况相关(r=0.45,P<0.05),无突变患者的LPL中位表达水平为0.006 0(0.000 7～0.110 0),明显高于突变患者的LPL中位表达水平[0.002 0(0.000 2～0.027 0)],差异有统计学意义(U=96.5,P<0.05);LPL表达水平与ZAP-70(r=0.38,P<0.05)及CD38(r=0.43,P<0.05)均显著相关.按照IgVH突变情况作为标准对LPL表达水平做ROC曲线分析,确定最佳分界值为0.036 0,敏感度为66.7%,特异度为72.4%,对IgVH突变情况阳性预测值(无突变)为51.8%,阴性预测值(有突变)为83.3%.结论 qRT-PCR方法检测LPL表达敏感可靠.LPL表达水平与CLL重要预后因素IgVH基因突变、ZAP-70、CD38密切相关,并可较准确地预测IgVH突变情况,在CLL的预后中具有重要价值.     

Expression of STK15 mRNA in hepatocellular carcinoma and its prognostic significance

ObjectivesTo investigate whether the STK15 mRNA expression correlates with clinicopathologic features and the prognosis of HCC patients.Design and methodsThree hepatoma cell lines, two normal liver epithelial cell lines, hepatoma tissues, adjacent tumor tissues and normal liver tissues were obtained from 46 HCC patients. Semi-quantitative RT-PCR assays were performed to detect the expression of STK15 mRNA in above cell lines and tissues. Moreover, the expression of STK15 protein in hepatoma tissues, adjacent tumor tissues and normal liver tissues was also examined by immunohistochemical staining. Finally, correlations between STK15 mRNA expression and the clinicopathological features and prognosis of HCC patients were evaluated.ResultsSTK15 mRNA showed higher levels in hepatoma cell lines than in normal liver epithelial cell lines. Moreover, the mean levels of STK15 mRNA and protein expression showed statistical difference between tumor tissues, tumor adjacent tissues and normal liver tissues (P < 0.01). By immunohistochemical analysis, we found that paraffin-embedded archival HCC tissues showed higher expression of STK15 than adjacent tumors and normal liver tissues. Furthermore, HCC patients with higher STK15 mRNA expression showed poorer prognosis than those with lower STK15 mRNA expression. The high level of STK15 mRNA expression was significantly correlated with tumor stage (P = 0.0081), more frequent lymph node (P = 0.0380) or hematogenous metastasis (P = 0.0066), and a higher incidence of cancer-related death (P = 0.0083). Furthermore, the disease-free survival (DFS) and overall survival (OS) rates of HCC patients with higher STK15 mRNA expression group (47.6% and 52.7%) were significantly lower than those of patients with low STK15 mRNA expression group (56.9% and 68.8%, P = 0.0018 and 0.0047).ConclusionsSTK15 mRNA might be a good marker for predicting the prognosis of HCC patients.     

uPA和P-P38在肝癌组织中的表达及相关性研究

目的 探讨尿激酶型纤溶酶原激活剂(uPA)和磷酸化P38(P-P38)在原发性肝癌(PHC)中的表达及其意义.方法 采用免疫组织化学S-P法检测34例原发肝癌组织、14例癌旁正常肝组织中uPA和P-P38的表达情况.结果 原发性肝癌组织中uPA和P-P38表达定位于细胞浆和细胞核,其表达明显高于癌旁正常肝组织(P＜0.05).二者的表达与性别、年龄、肿瘤大小等没有相关性(P＞0.05),与淋巴结转移、组织分化及癌栓等有关(P＜0.05),二者之间比较表达呈明显正相关(P＜0.05).结论 二者在原发性肝癌呈高表达,且与原发性肝癌的发生、发展和转移密切相关.     

原发性肝癌组织中甲胎蛋白mRNA定量检测的临床意义

目的研究肝细胞癌及癌旁组织甲胎蛋白mRNA定量检测的临床意义。方法用RT-PCR技术检测40例肝细胞癌和40例癌旁组织中甲胎蛋白mRNA。结果第一轮PCR扩增AFP mRNA,癌及癌旁组织阳性率分别为45%和20%,第二轮PCR癌及癌旁组织阳性率分别为80%和50%,癌组织AFP mRNA检出率高于癌旁组织。结论AFPmRNA的含量是判断肝癌预后的较好指标。对临床工作具有一定的指导意义。     

ZFYVE26在肝细胞癌中的表达及其意义

目的:探讨ZFYVE26在肝癌细胞株及肝细胞癌组织中的表达情况,为阐明ZFYVE26在肝癌发生发展中的作用提供依据.方法:应用荧光定量PCR方法检测正常肝脏细胞株L-02和肝癌细胞株MHCC-LM3中ZFYVE26 mRNA的表达情况.同时采用荧光定量PCR、Western Blot方法检测ZFYVE26在7例人肝细胞癌及其癌旁组织中的表达情况.结果:与L-02对比,ZFYVE26 mRNA在MHCC-LM3中的表达量明显降低,两组比较差异有统计学意义(P＜0.05);在肝细胞癌中,ZFYVE26基因及其蛋白的表达量均显著低于在癌旁组织中的表达(P＜0.05).结论:ZFYVE26在肝癌细胞株及肝细胞癌组织中的表达水平均明显降低,提示ZFYVE26的低表达与肝癌的发生发展有关.     

肝细胞癌中Livin mRNA与SMAC蛋白的表达

目的通过检测凋亡抑制因子（Livin mRNA）和凋亡促进因子（SMAC蛋白）在人肝细胞癌组织中的表达及相关性,分析其与肝细胞癌转移、复发的关系。方法通过反转录聚合酶链反应（RT-PCR）技术检测50例肝细胞癌和癌旁组织中Livin mRNA的表达;用免疫组化方法检测50例肝细胞癌和癌旁组织中SMAC蛋白表达水平。结果50例肝细胞癌组织中SMAC阳性率明显低于癌旁组织（P〈0．05）。Livin mRNA和SMAC的表达与门脉癌栓、术后复发、肝外转移及肿瘤细胞分化密切相关（P〈0．05）;SMAC的表达还与临床分期密切相关（P〈0．05）。Livin mRNA表达与SMAC蛋白表达呈显著负相关（P〈0．05）。结论Livin mRNA的高表达及SMAC的失活可能在肝细胞癌的发生及进展中起着重要作用。     

生长分化因子-15在垂体腺瘤中的表达及意义

目的探讨生长分化因子(GDF)-15在垂体腺瘤中的表达及意义。方法选择100例垂体腺瘤患者组织标本,根据是否具有侵袭性分为侵袭性垂体腺瘤63例和非垂体腺瘤37例,并选择同期在本院接受体检的健康人员50例作为对照组。比较各组受试者GDF-15的表达,并分析GDF-15和垂体腺瘤侵袭性的相关性。结果泌乳素垂体腺瘤与生长激素垂体腺瘤患者GDF-15均显著高于无功能性垂体腺瘤患者(P0.50);侵袭性垂体腺瘤患者GDF-15水平显著高于非侵袭性组及对照组(P0.05);GDF-15和侵袭性垂体腺瘤呈正相关(r=0.328,P=0.001)。结论在垂体腺瘤患者中,GDF-15的表达较高,且GDF-15水平和垂体瘤侵袭性存在相关性。     

PAIP1在肝细胞癌组织中的表达及临床意义

目的检测肝细胞癌组织及肝癌细胞株中PAIP1的表达水平,并分析其表达水平与肝细胞癌的临床病理特征参数的关系。方法采用实时荧光定量PCR(RT-PCR)、WB技术检测新鲜手术标本和肝癌细胞株的PAIP1的表达水平,采用免疫组化方法检测肝癌组织芯片PAIP1蛋白表达水平,比较肝癌组织和癌旁组织PAIP1的表达水平差异,在线工具分析肝癌数据库PAIP1的表达水平与病人临床病理参数的关联性。结果与癌旁组织相比,新鲜标本中癌组织PAIP1 mRNA的表达水平明显增高;PAIP1在肝癌细胞株中高表达;组织芯片中,PAIP1在细胞胞浆中表达,肝癌组织中PAIP1表达水平高于癌旁组织,PAIP1表达水平与与病人生存率呈负相关。结论肝细胞癌中PAIP1高表达,可能在肝细胞癌的发生、发展过程中发挥作用。